Autolus Therapeutics plc
AUTL
$2.12
-$0.11-4.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 191.89% | 83,655.17% | -- | -- | -10.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 191.89% | 83,655.17% | -- | -- | -10.99% |
| Cost of Revenue | 2.45% | 62.47% | 40.21% | 2,378.34% | 45.69% |
| Gross Profit | 45.21% | 10.14% | 12.36% | -381.87% | -73.48% |
| SG&A Expenses | 35.26% | -1.36% | 32.75% | 38.18% | 62.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.51% | 26.66% | 37.19% | 40.37% | 51.94% |
| Operating Income | 8.78% | 5.21% | -5.87% | -4.62% | -68.33% |
| Income Before Tax | -4.12% | -250.04% | 4.25% | 18.38% | -28.92% |
| Income Tax Expenses | -61.21% | -180.92% | 2,318.18% | 678.43% | 27,912.50% |
| Earnings from Continuing Operations | -2.05% | -227.22% | 3.63% | 17.77% | -33.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.05% | -227.22% | 3.63% | 17.77% | -33.16% |
| EBIT | 8.78% | 5.21% | -5.87% | -4.62% | -68.33% |
| EBITDA | 9.77% | 6.11% | -5.13% | -3.94% | -70.40% |
| EPS Basic | -2.05% | -227.29% | 3.63% | 17.81% | -11.13% |
| Normalized Basic EPS | -4.14% | -245.88% | 4.06% | 17.82% | -7.62% |
| EPS Diluted | -2.05% | -227.29% | 3.63% | 17.81% | -11.13% |
| Normalized Diluted EPS | -4.14% | -245.88% | 4.06% | 17.82% | -7.62% |
| Average Basic Shares Outstanding | 0.01% | -0.02% | 0.02% | 0.04% | 19.78% |
| Average Diluted Shares Outstanding | 0.01% | -0.02% | 0.02% | 0.04% | 19.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |